DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award | HT9425 23 KCRP PCFA

Opportunity Information: Apply for HT9425 23 KCRP PCFA

The FY23 DoD Kidney Cancer Research Program (KCRP) Postdoctoral and Clinical Fellowship Award is designed to support recent PhD-level graduates and medical school graduates who want to build a career focused on kidney cancer research during a postdoctoral and/or clinical fellowship period. The core goal is twofold: to fund innovative, high-impact kidney cancer research and to help the fellow gain the training, mentorship, and professional development needed to become an independent investigator and future leader in the field. Competitive applications are expected to make a clear case that the proposed work could meaningfully advance kidney cancer research and/or patient care, rather than adding a small incremental step.

A major emphasis of this opportunity is "impact." The program is looking for projects that can accelerate progress toward ending kidney cancer, whether the payoff is nearer-term or longer-term. Applicants are expected to be explicit about who benefits from the research, such as particular kidney cancer patient groups, people at elevated risk, or populations facing unique care barriers. The underlying theme is translation to benefit, even if the work is basic or early-stage, and reviewers will expect a credible path by which the findings could eventually influence understanding, diagnosis, prevention, or treatment.

The research strategy must be strong and well-justified, with a clear rationale, logical approach, and, when available, preliminary data. The program allows a range of project maturity, including high-risk/high-reward ideas that are still developing as well as more data-supported projects that are poised to move toward clinical translation. Regardless of maturity, proposals need to show rigorous design: adequate experimental detail, appropriate controls, a statistical plan, and thoughtful discussion of limitations, pitfalls, and alternative approaches. Human subjects research and work using human anatomical substances (such as patient samples and associated data) are allowed, but clinical trials are not permitted. The announcement draws a firm line between observational clinical research (allowed) and clinical trials (not allowed), defining a clinical trial as prospective assignment of human subjects to an intervention to evaluate biomedical or behavioral outcomes.

This award treats the fellow as the Principal Investigator (PI). That means the postdoc or clinical fellow is expected to lead the scientific narrative and write key application components, including the project narrative and a kidney cancer-focused researcher development plan, with guidance from a mentor. Prior kidney cancer experience is not strictly required for the PI, but both the proposed project and the training plan must be clearly centered on kidney cancer. Applications are expected to highlight the PI's potential to become independent through qualifications, achievements, honors, first-author papers, prior funding if applicable, and strong letters of recommendation.

Mentorship is a central review component. The mentor (or co-mentor) must demonstrate appropriate expertise in kidney cancer research and/or patient care, including recent publications and active funding, and must show a clear commitment to developing the fellow. If the primary mentor does not have established kidney cancer expertise, then a formal co-mentor who is an established kidney cancer researcher is required. The application should spell out how the mentor will support both the science and the fellow's trajectory, and while a limited history of mentoring trainees can be a weakness, the program indicates that a very strong and well-structured development plan can help offset it.

The researcher development plan is not a formality; it is one of the defining features of this mechanism. Applicants must describe why the training environment is well-suited, what individualized training and career development activities will be pursued, and how the plan will position the fellow to launch an independent kidney cancer research program. Multidisciplinary approaches are encouraged (for example, combining computational work with tumor biology, immunology, imaging, epidemiology, health services research, or disparities research), but they are not mandatory. If multidisciplinary elements are included, they should be clearly mapped to the training plan and the project goals.

From an administrative standpoint, awards are made as assistance agreements, meaning they will be issued either as grants or cooperative agreements depending on how much substantial involvement the Department of Defense anticipates having during performance. If the agency expects no substantial involvement, the award is typically a grant; if collaboration or other substantial involvement is anticipated, it may be a cooperative agreement, with those involvement details spelled out during negotiations. The awarding organization listed is the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding activity aligns with CFDA 12.420.

The program also signals alignment with broader federal priorities around metastatic and advanced cancers. It references recommendations from a congressionally mandated Metastatic Cancer Task Force and encourages applicants to consider ideas responsive to those recommendations as long as they fit within the kidney cancer program priorities and the limitations of this fellowship mechanism. In addition, collaborations between military or Veteran institutions and non-military institutions are strongly encouraged, particularly because these partnerships can provide unique clinical populations, data resources, and infrastructure that may improve the relevance of the research to Service members, military families, Veterans, and the general public.

Budget and funding expectations are relatively defined. The anticipated direct costs for the full period of performance should not exceed $195,000. The program expected to allocate about $1.25 million total to fund approximately four awards, though final numbers depend on federal funding availability and the results of scientific and programmatic review. Awards were expected to be made no later than September 30, 2024, and FY23 funds supporting awards were anticipated to remain available for use until they expire on September 30, 2029, which effectively sets an outer boundary for the period in which those obligated funds can be spent.

Finally, applicants proposing research with humans or animals should plan for DoD-specific regulatory steps beyond typical university processes. Human research involving data, tissues, specimens, or interaction with subjects requires review by the USAMRDC Office of Human and Animal Research Oversight, specifically the Office of Human Research Oversight, in addition to local IRB or ethics committee approval, and this extra review can take up to about three months after complete submission. Multi-site, non-exempt human subjects research must comply with the single-IRB requirement under 45 CFR 46.114(b), and applications should include a plan for single-IRB arrangements when multiple domestic institutions are involved. Animal studies require local IACUC review plus DoD-level review by ACURO, which can take three to four months, and applicants are expected to plan for rigorous, reproducible preclinical study design and reporting consistent with widely recognized standards such as ARRIVE guidelines.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Postdoctoral and Clinical Fellowship Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 02, 2023.
• Applicants must submit their applications by Aug 03, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 4 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 KCRP PCFA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: